/

INM

InMed Pharmaceuticals Inc.After hours

1.31−0.02 −1.50%USD

NasdaqCM · as of Oct 14, 16:00 ET · 15m delay

Open

1.35

Prev close

1.33

Day range

1.311.36

52-week range

0.57502.33

Volume

29.77K0.03×

Mkt cap

7.20M

P/E ttm

—

Fwd P/E

-0.21

EPS ttm

-2.84

Div yield

0.00%

Earnings

—

From 52w high

−43.78%

Price Chart

Yahoo Finance · delayed

INMOct 14, 2026O 1.35H 1.36L 1.31C 1.31−0.02 (−1.50%)Vol 29.77K

SMA 501.38
SMA 2001.18

1Y change −38.50% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INM InMed Pharmaceuticals Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.50%
1 month: +0.77%
3 months: −17.61%
6 months: +83.99%
Year to date: +23.58%
1 year: −40.45%

Valuation & ownership

Market cap: 7.20M
Enterprise value: 5.07M
P/E (ttm): —
Forward P/E: -0.21
PEG ratio: —
Price / book: 6.52
Price / sales (ttm): —
EV / EBITDA: -0.52
EPS (ttm): -2.84
EPS (forward): -6.25
Beta (5y monthly): 0.93
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 5.49M
Float: 3.08M
Short % of float: 0.62%
Short ratio (days): 0.52
Held by insiders: 0.06%
Held by institutions: 53.30%
Avg volume (3m): 914.81K
50-day average: 1.39
200-day average: 1.18
52-week change: −40.45%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 40.6
vs 50-day SMA: −5.23%
vs 200-day SMA: +10.61%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.81%
Realised vol (20d, ann.): 36.3%
From 52-week high: −43.78%
From 52-week low: +127.83%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About InMed Pharmaceuticals Inc.

Yahoo Finance profile

InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 6
Headquarters: Vancouver, BC, Canada
Website: inmedpharma.com
Officers: Mr. Eric A. Adams B.S. Chem., M.I.B. President, CEO & Director
Ms. N. Netta Jagpal CFO & Corporate Secretary
Mr. Michael Woudenberg P.Eng. Chief Operating Officer
Dr. Eric Chih-Hsien Hsu Ph.D. Senior Vice President of Preclinical Research & Development

SEAS

Seasonality · INM

2014–2026 · monthly returns

Strongest month Jan +12.09%Weakest month Jul −17.42%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	3.8	-22.7	-24.1	11.6	118.1	-1.3	-5.2	-8.2	0.7	-3.7			+23.6%
2025	-35.0	-4.5	-29.6	43.7	-16.3	30.5	-25.2	-8.6	-1.4	-14.2	-29.3	-20.3	−77.6%
2024	-13.5	15.3	-12.3	-28.6	13.5	-9.8	-33.8	101.7	-33.2	12.2	-19.4	10.5	−43.0%
2023	-8.9	-27.7	-18.8	11.1	11.7	-30.8	20.8	-26.7	-14.7	-30.9	-9.1	-5.5	−79.4%
2022	-7.6	-22.1	0.1	-3.5	-15.4	-39.0	-17.0	-39.0	10.8	-53.7	-13.1	-23.8	−93.8%
2021	28.0	0.2	-21.8	13.3	-21.1	7.8	-12.3	-20.8	-20.8	-12.9	24.6	-31.1	−60.2%
2020	50.0	-5.2	-39.5	-2.6	57.6	-21.4	-36.6	7.7	-19.9	-1.0	8.5	-9.1	−44.6%
2019	91.8	-10.2	-5.0	-18.5	-13.2	-12.5	-18.6	28.6	-20.7	-15.0	1.6	-2.7	−29.4%
2018	-10.9	-26.9	55.0	-20.8	-8.1	-26.6	3.3	6.1	-1.6	-33.9	-4.6	-34.8	−76.1%
2017	51.2	7.8	29.2	39.7	-38.0	-17.4	1.2	-17.0	86.0	-10.8	47.1	102.9	+526.5%
2016	13.0	-12.3	-21.1	-15.6	-13.2	18.2	-11.5	0.0	44.9	39.0	-17.3	47.8	+47.8%
2015	-25.0	200.0	-11.1	0.0	-33.3	5.6	-32.0	27.0	-19.2	0.8	-0.8	-2.5	−4.2%
2014						67.8	-47.3	-6.7	-28.3	-19.0	-4.3	-22.6	−64.5%

INSD

Insider Activity · INM

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 7, 2026	Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.33 per share.	10.9K	$14.48K
Oct 4, 2026	Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.33 per share.	42.9K	$57.08K
Sep 15, 2026	Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.29 - 1.30 per share.	91.1K	$118.08K
Jul 15, 2026	Vivo Opportunity LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.55 per share.	20.5K	$31.85K
Jul 14, 2026	Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.56 per share.	1K	$1.55K
Jul 1, 2026	Vivo Opportunity LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.54 - 1.55 per share.	6.6K	$10.15K
Jun 7, 2026	Vivo Opportunity LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.52 - 1.69 per share.	249.2K	$391.56K
May 18, 2026	Adar1 Capital Management LlcBeneficial Owner of more than 10% of a Class of Security	Purchase at price 1.50 - 1.60 per share.	468.6K	$721.55K

INM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About InMed Pharmaceuticals Inc.

Seasonality · INM

Insider Activity · INM

Congress Trades · INM

Investors Holding INM

Investors Holding INM

Congress Trades · INM

Insider Activity · INM

Seasonality · INM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About InMed Pharmaceuticals Inc.

Earnings & Dividends

News